A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs - Réa, Delphine; Mauro, Michael J.; Boquimpani, Carla; Minami, Yosuke; Lomaia, Elza; Voloshin, Sergey; Turkina, Anna; Kim, Dong-Wook; Apperley, Jane F.; Abdo, Andre; Fogliatto, Laura Maria; Kim, Dennis Dong Hwan; et al. (Blood, 2021)
Keywords: Adult; Aged; Aged, 80 and over; Aniline Compounds - adverse effects; Aniline Compounds - therapeutic use; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Female; Humans; Leukemia, Myeloid, Chronic-Phase - drug therapy; Male; Middle Aged; Niacinamide - adverse effects; Niacinamide - analogs & derivatives; Niacinamide - therapeutic use; Nitriles - adverse effects; Nitriles - therapeutic use; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Pyrazoles - adverse effects; Pyrazoles - therapeutic use; Quinolines - adverse effects; Quinolines - therapeutic use; Treatment Outcome; Young Adult